1.	Phase II/III Study of Neoadjuvant Therapy Comprising Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (Abraxane®) in Women With Previously Untreated, Unresected, Stage II-IIIB Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WHC-MRI-GU-2006-097, NCT00397761
2.	A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0553C, NCT00659269
3.	Phase III Randomized Study of Paclitaxel Versus Paclitaxel Albumin-Stabilized Nanoparticle Formulation Versus Ixabepilone in Combination With Bevacizumab in Patients With Locally Recurrent, Stage IIIB or IV Breast Cancer Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
4.	A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA046, NCT00844649
5.	A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: CA033, NCT00864253
6.	Phase I/II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Pemetrexed Disodium in Patients With Advanced Non-Small Cell Lung Cancer, Breast Cancer, or Other Solid Tumors Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UCD-185, UCDCC-185, UCD-200614714, NCT00470548
7.	Phase I/II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Carboplatin, and Concurrent Radiotherapy Followed by Consolidation Chemotherapy Comprising Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: VU-VICC-THO-0746, VICC-THO-0746, NCT00544648
8.	Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07-069, NCT00570674
9.	Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: AAAC1114, NCT00583349
10.	A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 19 and over Sponsor: Other Protocol IDs: VAST-B, NCT00748553
11.	Phase I/II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, Cetuximab, and Radiotherapy in Patients With Local-Regionally Advanced Squamous Cell Carcinoma of the Head and Neck Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: SCCC-112008-019, 112008-019, ABX 236-HN08US, NCT00851877
12.	Phase I/II Study of Weekly Abraxane (Paclitaxel Albumin-Stabilized Nanoparticle Formulation) and RAD001 (Everolimus) in Women With Locally Advanced or Metastatic Breast Cancer: A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CINJ-040803, 040803, NOVARTIS-CINJ-040803, NCT00934895
13.	Phase II Study of ABI-007 in Patients With Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: GOG-0127V, GOG-0127V, NCT00309959
14.	Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TK001, NCT00284752
15.	Phase II Study of Sargramostim (GM-CSF) and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Patients With Platinum-Resistant Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UWCC-6168, 6168, UWCC-UW-6168, UWCC-06-9975-H/B, UWCC-UW-128, ABRAXIS-FHCRC-6168, NCT00466960
16.	First Line Therapy for Patients With Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA042, NCT00456846
17.	Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: WIRB#20051730, NCT00466986
18.	Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCC 02106, NCT00472693
19.	Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DCRO_BR_2006_01, NCT00479674
20.	Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0495-2006, NCT00503750
21.	Phase II Study of Paclitaxel Albumin-Stabilized Nanoparticle Formulation (Abraxane) and Carboplatin in Patients With Extensive-Stage Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: UNC-LCCC-0519, LCCC 0519, NCT00454324
22.	Phase II Study of Induction Chemotherapy Comprising Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Concurrent Thoracic Radiotherapy and Erlotinib Hydrochloride in Patients With Poor-Risk, Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-30605, CALGB 30605, NCT00553462
23.	Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2007.061, NCT00585689
24.	Phase II Randomized Study of Neoadjuvant Therapy Comprising Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation With Versus Without Vorinostat in Women With HER2-Negative Primary Operable Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-SKCCC-J0785, SKCCC J0785, NCT00616967
25.	Phase II Study of Age-Related Changes in Pharmacokinetics and Pharmacodynamics of Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Patients With Metastatic Breast Cancer Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CHNMC-07157, 07157, ABRAXIS-ABX206-BC07US, NCT00609791